Updated:
Finistere Ventures
Finistere Ventures launched in 2005, founded by Arama Kukutai and Spencer Maughan with roots in New Zealand's pastoral and dairy innovation ecosystem.
Finistere Ventures
Finistere Ventures launched in 2005, founded by Arama Kukutai and Spencer Maughan with roots in New Zealand's pastoral and dairy innovation ecosystem. What began as a regional investment vehicle evolved into a trans-Pacific platform when the firm opened offices in San Diego and Palo Alto, later adding a Dublin presence to capture European agtech innovation. Finistere's distinctiveness stems from running capital through both hemispheres simultaneously — rare among agrifood investors who typically cluster in one geography. The firm deploys across seed, early-stage, and growth rounds, targeting companies that apply biotech, digital agronomy, and supply-chain technology to the food system. Its portfolio reflects a deliberate mix of biological and digital bets: Finistere backed New Zealand-based Biolumic, a UV light seed treatment platform, and co-invested alongside Syngenta Ventures in Taranis, an AI-powered crop intelligence company based in Israel. The firm also participated in CropX's $30M Series C in 2022, an Israel-rooted soil sensing company now operating globally. Finistere anchors its strategy in direct equity positions, occasionally syndicating with corporate venture arms like Corteva and Nutrien, rather than running a fund-of-funds model. Geographically, the firm maintains active deal flow across North America, Israel, New Zealand, and Ireland. Team size remains deliberately lean — typical for a sector-specialist venture platform — with partners operating from both US coasts and across time zones in Australasia. In November 2023, the firm filed a regulatory notice for a new pooled investment fund, signaling continued capital formation activity despite the broader venture pullback (per SEC filing, 2023). Finistere has historically been linked to Pavilion Capital, the Singapore-based Temasek affiliate, as a LP anchor in its earlier funds. The firm does not appear to operate a disclosed philanthropic arm or adjacent club-vehicle structure, keeping its capital operations concentrated within the fund format. Finistere's structural differentiator lies in its deliberate straddle of the agricultural science–venture capital divide. Most agtech funds either lean heavily into software-only plays or lack boots-on-the-ground presence in farming regions. Finistere maintains operational linkages with New Zealand's Crown Research Institutes and the country's pastoral R&D infrastructure, giving it access to early-stage biotech and agronomy innovation that traditional Silicon Valley venture shops rarely see. That sourcing architecture, combined with US commercialization pathways through its California offices, creates a dual-track pipeline no other agtech venture firm replicates at sub-$500M scale.
General information
Firm type
Venture Capital
Year founded
2005
AUM
$250M - $500M (Altss estimate)
Location
Region
North America
Country
United States
City
Newport Beach
Corporate office
Newport Beach, CA, United States
Additional offices
San Diego, CA · Palo Alto, CA · Dublin, Ireland · Wellington, New Zealand
Principals
Arama Kukutai
Co-Founder & Partner
Spencer Maughan
Co-Founder & Partner
Dean Didato
Partner
Ingrid Fung
Director
David Pierson
Venture Partner
Sector focus
Frequently asked questions
How does Finistere Ventures source its agtech deal flow differently from other venture firms?
Finistere's sourcing architecture operates across both hemispheres simultaneously through offices in New Zealand, Ireland, and California. The firm's New Zealand origins give it direct access to Crown Research Institute spinouts and pastoral R&D innovations often invisible to US-centric investors. This trans-Pacific structure allows Finistere to identify biological and digital agtech companies at earlier stages, then commercialize them through US market pathways.
What investment stages does Finistere typically target?
Finistere deploys across the full venture spectrum, from seed to growth-stage rounds. The firm's portfolio historically spans pre-revenue biotech platforms, early-stage digital agronomy tools, and later-stage companies with proven commercial traction. This stage flexibility reflects the varied development timelines inherent in agricultural technology, where biological solutions mature more slowly than pure software plays.
Who are Finistere's typical co-investors or LP anchor relationships?
The firm has co-invested alongside corporate venture arms including Syngenta Ventures, Corteva, and Nutrien, particularly in digital agronomy and crop-input companies. In earlier fund vintages, Finistere was reportedly anchored by Pavilion Capital, the Temasek-affiliated Singapore entity. This corporate-syndication pattern reflects Finistere's role as a bridge between institutional venture capital and strategic agriculture corporates.
Does Finistere participate in fund commitments or only direct deals?
Finistere primarily executes direct equity investments into agrifood technology companies rather than operating as a fund-of-funds. The firm's regulatory filings and portfolio history indicate direct positions, often syndicating with strategic corporate investors. There is no public record of Finistere making LP commitments into external venture funds.
What is Finistere's geographic investment footprint?
The firm actively deploys across four primary innovation corridors: North America (US and Canada), Israel, New Zealand, and Ireland. This footprint mirrors the global distribution of agtech innovation clusters — Israel's precision agriculture and irrigation technology, New Zealand's pastoral biotech and dairy science, Ireland's agri-food R&D ecosystem, and the US's broad agtech commercialization market.
Which sectors does Finistere explicitly avoid?
Finistere concentrates strictly on agrifood technology and adjacent climate applications, deliberately avoiding generalist enterprise software, consumer internet, or therapeutics despite overlapping science. There is no evidence the firm invests in pure-play healthcare biotech or fintech, keeping its portfolio boundaries tightly drawn around the food and agriculture system.
How is Finistere structured relative to New Zealand's innovation ecosystem?
Finistere's New Zealand heritage is more than historical — the firm maintains operational linkages with the country's Crown Research Institutes and pastoral innovation infrastructure. This gives Finistere proprietary access to technologies spun out of New Zealand's publicly funded agricultural science, which the firm then seeks to commercialize globally through its US and European offices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: